Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Uric acid transport" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
HURAT1 (human urate anion transporter 1) inhibitors and application thereof
ActiveCN108727267AEnhanced inhibitory effectOrganic active ingredientsOrganic chemistryUric acid transportURAT1 Inhibitors
The invention belongs to the field of medicinal chemistry and particularly relates to hURAT1 (human urate anion transporter 1) inhibitors and an application thereof. Specifically, the hURAT1 inhibitors are compounds with structure shown as formula (I) or (II) in the description or pharmaceutically acceptable salts of the compounds. Experiments prove that the compounds have good inhibition effect on uric acid transport of the hURAT1 in an HEK293 transfection cell, which shows that the compounds have good application prospect in treatment of hyperuricemia or gout.
Owner:JIANGSU ATOM BIOSCI & PHARMA CO LTD
Application of fisetin in preparation of medicine for preventing and treating uric acid nephropathy
InactiveCN112755018AAccelerated excretion ratePrevent fibrosisOrganic active ingredientsSkeletal disorderPharmaceutical SubstancesBlood uric acid
The invention relates to application of fisetin in preparation of a medicine for preventing and treating uric acid nephropathy, and belongs to the field of medicine. The invention provides application of fisetin or salt thereof in preparation of the medicine for treating and / or preventing the uric acid nephropathy. Animal experiments prove that the fisetin can regulate protein expression of kidney urate transporters URAT1, OAT1, OAT3 and ABCG2, improve uric acid excretion rate and obviously reduce serum creatinine, blood urea nitrogen and blood uric acid levels, also has an effect of inhibiting renal interstitial fibrosis, can obviously reduce expression quantities of fibrosis-related proteins such as alpha-SMA, cologen I and fibronectin, has an exact prevention / treatment effect on the uric acid nephropathy and provides a new choice for clinical medication.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
URAT1 (uric acid transporter 1) inhibitors, and preparation method and application thereof
InactiveCN108658879AEnhanced inhibitory effectUniversalOrganic active ingredientsOrganic chemistryDrugURAT1 Inhibitors
The invention provides carboxylic acid URAT1 inhibitors containing a naphthylmethyltriazole structure and represented by a general formula (I) which is described in the specification, a preparation method for the inhibitors, pharmaceutical compositions containing the inhibitors, and application of the inhibitors to preparation of drugs used for treating hyperuricemia and gout. The inhibitors as shown in the formula (I) have strong URAT1 inhibitory effect, normally have much stronger inhibitory effect compared with conventional URAT1 inhibitors with the structural characteristic that triazole and a naphthalene ring are directly linked by a covalent bond, and can be used as active ingredients for preparation of therapeutics used for treating gout and hyperuricemia. The inhibitors as shown inthe formula (I) are effective in wide dosage range; for example, the dosage of the inhibitors is about 1-1000 mg for each person each day.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Triazole malonic acid compounds as well as preparation method and application thereof
The invention relates to the field of medicines related to hyperuricemia and gout and in particular relates to urate transporter I (URAT1) inhibitors containing triazole malonic acid structures, a preparation method thereof, a medicine composition containing the URAT1 inhibitors and an application of the URAT1 inhibitors and the medicine composition to preparation of diabetes medicines. In a general formula in the specification, R is selected from H, C1-C8 alkyl and C3-C6 cycloalkyl.
Owner:张远强
Halonaphthalene-ring-containing butanedioic acid amide derivatives, preparing method thereof and uses of the derivatives
InactiveCN104311442AOrganic active ingredientsOrganic compound preparationDiabetes mellitusUric acid transport
The invention relates to the field of medicines related to hyperuricemia and gout, and particularly relates to urate transporter 1 inhibitors having structures of halonaphthalene-ring-containing butanedioic acid amides, a preparing method thereof, pharmaceutical compositions containing the inhibitors and applications of the inhibitors in preparation of medicines for diabetes. A formula (I) is shown in the specification, wherein substituents are shown in the specification.
Owner:天津华祥医药科技有限公司
Compounds containing tetrazoleacetic acids as well as preparation method and application of compounds
The invention relates to the field of medicines related to hyperuricemia and gout and in particular relates to urate transporter I (URAT1) inhibitors containing tetrazoleacetic acid structures, a preparation method of the URAT1 inhibitors, a medicine composition containing the URAT1 inhibitors and an application of the URAT1 inhibitors and the medicine composition to preparation of diabetes medicines. In a general formula, R<1> is selected from H, C1-C5 alkyl and C3-C6 cycloalkyl.
Owner:茅婷婷
Succinic acid amide derivatives containing phenylnaphthalene rings as well as preparation method and application thereof
InactiveCN104292123AHigh activityOrganic active ingredientsOrganic compound preparationButanedioic acidURAT1 Inhibitors
The invention relates to the field of medicines related to hyperuricemia and gouts and in particular relates to urate transporter 1 (URAT1) inhibitors of succinic acid amide structures containing phenylnaphthalene rings, a preparation method thereof, a medicine composition containing the URAT1 inhibitors and an application of the URAT1 inhibitors and the medicine composition in preparation of diabetes medicines. R<1> and R<2> in a general formula are defined in the specification.
Owner:崔玲玲
Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same
ActiveUS20200140423A1Significant inhibitory activityOrganic active ingredientsOrganic chemistryDiseaseUric acid transport
The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and application of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.
Owner:DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO LTD
Salts and co-crystals of lesinurad
Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
Owner:CRYSTAL PHARMATECH CO LTD +1
Genipin derivative with uric acid transport promoting activity and preparation method thereof
ActiveCN111518072AFacilitates transport activityLow priceOrganic chemistrySkeletal disorderDrug biological activityMethyl palmoxirate
The invention discloses a genipin derivative with uric acid transport promoting activity and a preparation method, and belongs to the field of genipin derivative preparation. The genipin derivative with uric acid transport promoting activity comprises geniposide, sulfuric acid, methanol, dichloromethane, triethylamine and p-toluenesulfonyl chloride. According to the invention, a novel methyl genipin derivative is synthesized, has an activity effect of promoting uric acid transport, and is subjected to corresponding biological activity detection; according to the invention, the biological activity of genipin is improved by carrying out structural modification on genipin, and the invention has important practical significance for researching and developing a novel drug for promoting uric acid transport; according to the genipin derivative capable of promoting uric acid transport, geniposide is used as a raw material for related structural modification, the synthesis method is simple, theprice of the raw material is low, and the structure is novel.
Owner:INST OF AGRO FOOD SCI & TECH SHANDONG ACAD OF AGRI SCI
Crystalline forms of lesinurad and its sodium salt
Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
Owner:CRYSTAL PHARMATECH CO LTD +1
Triazolesulfonylmalonic acid compounds as well as preparation method and application thereof
The invention relates to the field of medicines related to hyperuricemia and gout and in particular relates to urate transporter I (URAT1) inhibitors containing triazolesulfonylmalonic acid structures, a preparation method thereof, a medicine composition containing the URAT1 inhibitors and an application of the URAT1 inhibitors and the medicine composition to preparation of diabetes medicines. In a general formula in the specification, R is selected from H, C1-C8 alkyl and C3-C6 cycloalkyl.
Owner:SHANDONG XINGQIANG CHEM IND TECH RES INST CO LTD
Tetrazoleacetic acid compound, as well as preparation method and applications thereof
ActiveCN104341367AHigh activityOrganic chemistrySkeletal disorderChemistryUric Acid Transporter-1 Inhibitors
The invention relates to the field of medicaments related to hyperuricemia and gout. In particular, the invention relates to a tetrazoleacetic acid structure-containing uric acid transporter 1 inhibitor, a preparation method thereof, a medicament composition containing the inhibitor, and applications of the inhibitor to preparation of diabetes medicaments. The structural formula is shown in the specification, wherein R<1> is selected from H, alkyls of C1-C5, and cycloalkyls of C3-C6.
Owner:符瑶
A dna fragment for uric acid-induced expression of target protein, related promoter and application
The invention discloses a DNA fragment for uric acid-induced target protein expression, a related promoter and application. The present invention provides a DNA molecule whose nucleic acid sequence is the 143-200 nucleotides from the 5' end of sequence 1 in the sequence listing. DNA fragments containing the above DNA molecules are also within the scope of the present invention. The experiments of the present invention prove that the present invention obtains a new promoter by transforming the -35 and -10 regions of the lac promoter of Escherichia coli, which can utilize uric acid under the cooperation of the uric acid regulatory protein HucR and the uric acid transporter YgfU Induce the expression of the target protein. Therefore, the promoter and related expression system of the present invention can be used to express the target protein under the induction of uric acid, and can also be used in a biological uric acid detection system.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application
ActiveCN107176930BStrong inhibitory activityNo serious side effectsOrganic active ingredientsOrganic chemistryLesinuradSide effect
![2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/2bfa73f7-eeac-4fb7-9dca-2fb822a5385f/BSA0000139037550000031.png "2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application")
![2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/2bfa73f7-eeac-4fb7-9dca-2fb822a5385f/BSA0000139037550000041.png "2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application")
![2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/2bfa73f7-eeac-4fb7-9dca-2fb822a5385f/BSA0000139037550000042.png "2-[5-bromo-4-(4-fluorocyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio]acetic acid compound and its application")
Owner:GUANGDONG SCI FINDER PHARMA TECH CO LTD
Alkoxy-substituted triazole malonate type compound, and preparation method and application thereof
The invention relates to the field of medicaments associated with hyperuricemia and gout. Specifically, the invention relates to a urate transporter 1 inhibitor with an alkoxy-substituted triazole malonate structure, a preparation method of the urate transporter 1 inhibitor, a pharmaceutical composition containing the urate transporter 1 inhibitor and application of the urate transporter 1 inhibitor in preparation of diabetic medicaments. The structural formula is shown in the specification, wherein R is selected from H, alkyl of C1-C8 and cycloalkyl of C3-C6.
Owner:浙江西塘实业有限公司
Application of turmeric element in the preparation of medicament for restraining uric acid transportor URAT1
ActiveCN100571692CExact regulationExact inhibitory regulationSkeletal disorderKetone active ingredientsDiseaseUric acid transport
The invention relates to a new application of curcumin, a flavonoid monomer compound, in particular to the application of curcumin in the preparation of uric acid transporter URAT1 inhibitory drugs. The results of animal experiments show that curcumin has a definite inhibitory effect on the expression of uric acid transporter URAT1, which is abnormally increased in hyperuricemia model animals, but has no significant inhibitory effect on the normal level of uric acid transporter URAT1 expression in normal animals. Safety, using curcumin with related pharmaceutical excipients, conventional preparation methods can be used to make curcumin oral liquid, capsules, tablets, granules and other uric acid transporter URAT1 inhibitory drugs, which can be used for the treatment of uric acid transporter Diseases associated with abnormally high expression of sub-URAT1.
Owner:NANJING UNIV
Succinic acid amide derivatives of methoxynaphthalene ring, its preparation method and use
InactiveCN104193644BHigh activityOrganic active ingredientsOrganic compound preparationButanedioic acidSuccinic acid
Owner:NANTONG ZHENGDA AGROCHEM
Nitrophenyl substituted naphthalene cyclosuccinic acid amide derivatives, preparation method and use thereof
ActiveCN104292124BHigh activityOrganic active ingredientsOrganic compound preparationUric acid transportDiabetes mellitus
The invention relates to the field of medicines related to hyperuricemia and gout. Specifically, the present invention relates to a class of uric acid transporter 1 inhibitors of nitrophenyl substituted naphthalene cyclosuccinic acid amide structures, their preparation methods, pharmaceutical compositions containing them, and their application in the preparation of diabetes drugs . (I ) Wherein, R1 is selected from H and halogen substituents.
Owner:茅婷婷
A kind of pharmaceutical composition containing uric acid transport protein inhibitor and preparation method thereof
The invention relates to a pharmaceutical composition containing a uric acid transport protein inhibitor and a preparation method thereof. Specifically, the pharmaceutical composition contains 1-((6-bromoquinolin-4-yl)thio)cyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof, and low-substituted hydroxypropyl cellulose, and the pharmaceutical composition The product has good dissolution rate and excellent stability.
Owner:FUJIAN SHENGDI PHARM CO LTD +1
Novel salts and co-crystals of lesinurad
ActiveUS20160347722A1Process environmental protectionOrganic chemistry methodsDiseaseUric acid transport
Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
Owner:CRYSTAL PHARMATECH CO LTD +1
Nitronaphthalene-ring-containing butanedioic acid amide derivatives, preparing method thereof and uses of the derivatives
ActiveCN104311444AHigh activityCarboxylic acid nitrile preparationOrganic compound preparationDiabetes mellitusUric acid transport
The invention relates to the field of medicines related to hyperuricemia and gout, and particularly relates to urate transporter 1 inhibitors having structures of nitronaphthalene-ring-containing butanedioic acid amides, a preparing method thereof, pharmaceutical compositions containing the inhibitors and applications of the inhibitors in preparation of medicines for diabetes. A formula (I) is shown in the specification, wherein R1 is selected from -NO2 and -CN, and R2 is selected from H, C1-C5 alkyl and C3-C6 cycloalkyl.
Owner:茅婷婷
Traditional Chinese medicine gout-dispelling tea drink capable of reducing uric acid and preparation method thereof
PendingCN113876898AAchieve inhibitionLower uric acid levelsDispersion deliverySkeletal disorderUric acid transportChinese Chive
The invention discloses a traditional Chinese medicine gout-dispelling tea drink capable of reducing uric acid and a preparation method thereof, and particularly relates to the technical field of traditional Chinese medicine drinks. The traditional Chinese medicine gout-dispelling tea drink comprises the following components in parts by weight: 20-40g of corn stigma, 10-30g of Chinese chive seeds, 20-40g of semen plantaginis, 20-40g of poria cocos, 20-40g of pawpaw, 10-30g of mulberry, 20-40g of semen coicis and 4-8g of cinnamon. According to the traditional Chinese medicine gout-dispelling tea drink, the inhibition effect on uric acid is realized through the uric acid transporter URAT1 inhibition effect of mulberry, the inhibition effect IC50 is 1 / 62 of that of a decoction stock solution, and the uric acid content in a human body is further reduced, so that the effect of reducing the uric acid content in the human body is realized.
Owner:合肥安药会健康产业有限公司
3-(naphthalene-1-methyl substituted) pyridine derivative and synthesis method and application thereof
ActiveCN108440397APromote excretionStrong inhibitory activityOrganic chemistrySkeletal disorderDiseaseTreatment effect
The invention discloses a 3-(naphthalene-1-methyl substituted) pyridine derivative and a synthesis method and application thereof. The derivative comprises a compound having a structural formula as shown in the specification, or a pharmaceutically acceptable salt, hydrate, solvate, polymorphic substance, tautomer, stereoisomer or prodrug thereof, the derivative has high hURAT1(human urate transporter) inhibitory activity, has strong uric acid transport inhibitory activity of MDCK-hURAT1 cells, can be used for preparation of drugs for treatment and / or prevention and / or delay and / or adjuvant treatment and / or treatment of diseases associated with hURAT1 (human urate transporter) transport uric acid, especially hyperuricemia. By combining with other drugs for treatment of the hyperuricemia,the derivative is expected to achieve better therapeutic effects on the hyperuricemia.
Owner:SOUTHERN MEDICAL UNIVERSITY
Lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout
ActiveCN112481172ADecreased xanthine oxidase (XOD) activityLower serum uric acid levelsBacteriaLactobacillusLactobacillus rhamnosusTG - Triglyceride
The invention discloses lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CCFM1130 disclosed by the invention can be used for reducing the serum uric acid level of a hyperuricemia mouse, inhibiting the xanthine oxidase (XOD) activity of serum and a liver, reducing the occurrenceof hyperuricemia and gout, down-regulating serum blood sugar, serum total triglyceride (TG), and serum total cholesterol (TC) level, and inhibiting serum alkaline phosphatase (ALP) activity; and theexpression of the ileum uric acid transport protein ABCG2 is promoted. The lactobacillus rhamnosus CCFM1130 disclosed by the invention can tolerate the gastrointestinal tract environment, can be usedfor preparing functional microbial inoculants, foods and medicines capable of alleviating hyperuricemia and gout and capable of being taken into gastrointestinal tracts, and has a wide application prospect.
Owner:JIANGNAN UNIV
A nitro-substituted triazole sulfinyl malonate compound, its preparation method and use
ActiveCN104326993BHas formula IHigh activityOrganic active ingredientsOrganic chemistryDiabetes mellitusUric acid transport
Owner:山东产研中科高端化工产业技术研究院有限公司
DNA fragment used for uric-acid-induced target protein expression and related promoter and applications thereof
The invention discloses a DNA fragment used for uric-acid-induced target protein expression and a related promoter and applications thereof. A DNA molecule is provided. The nucleic acid sequence of the DNA molecule is shown as the number 143 to the number 200 nucleic acids from the 5' tail end of the sequence 1 in a sequence table. The DNA fragment containing the DNA molecule is also provided by the invention. Experiments show that: a novel promoter is obtained by modification of the -35 area and the -10 area of an escherichia coli lac promoter, and the promoter can induce target protein expression by utilization of uric acid under the cooperation of a uric acid regulatory protein HucR and a uric acid transport protein YgfU. The novel promoter and a related expression system can be used for target protein expression under induction of uric acid and can be used for biological uric acid detection systems.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Alkoxy-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof
The invention relates to the field of medicaments associated with hyperuricemia and gout. Specifically, the invention relates to a urate transporter 1 inhibitor with an alkoxy-substituted triazole sulfinyl malonate structure, a preparation method of the urate transporter 1 inhibitor, a pharmaceutical composition containing the urate transporter 1 inhibitor and application of the urate transporter 1 inhibitor in preparation of diabetic medicaments. The structural formula is shown in the specification, wherein R is selected from H, alkyl of C1-C8 and cycloalkyl of C3-C6.
Owner:HAIMEN CANGYUN MACHINERY CO LTD
Urat1 inhibitor for promoting uric acid excretion
ActiveUS20200262832A1Enhanced inhibitory effectGood application prospectOrganic active ingredientsIsotope introduction to heterocyclic compoundsUric acid transportURAT1 Inhibitors
The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.
Owner:JIANGSU ATOM BIOSCI & PHARMA CO LTD
Alkoxyl-substituted triazole sulfonyl propane diacid compounds, preparation method and use thereof
InactiveCN104311498AHigh activityOrganic chemistrySkeletal disorderUrate Transporter-1 InhibitorsDiabetes mellitus
The invention relates to the field of medicaments which are associated with hyperuricemia and gout and particularly relates to urate transporter 1 inhibitors which contain alkoxyl-substituted triazole sulfonyl propane diacid structures, a preparation method thereof, a pharmaceutical composition containing the urate transporter 1 inhibitors and application of the urate transporter 1 inhibitors in preparation of diabetes drugs. The formulae of the urate transporter 1 inhibitors are shown in the specification, wherein R is selected from H, C1-C8 alkyl and C3-C6 cycloalkyl.
Owner:李德松
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com